Arsenic is a toxic metalloid contaminant in drinking water sources throughout the world, affecting hundreds of millions of people ([@r29]). Exposure to arsenic via drinking water in early life has been shown to increase the risk of mortality from bronchiectasis ([@r47]). Bronchiectasis unrelated to cystic fibrosis (CF) is a chronic, progressive lung disease characterized by cough and sputum production, periodic infectious exacerbations, and premature death in adulthood ([@r13]). Bronchiectasis associated with CF is thought to arise from impaired innate immune pathways in the lung ([@r2]), and although the pathology of non-CF bronchiectasis is poorly understood, similar mechanisms are likely to be involved ([@r13]). The processes linking arsenic exposure in early life and the development of bronchiectasis are unclear.

There is evidence for an effect of *in utero* arsenic exposure on innate immunity. Arsenic exposure during pregnancy induces oxidative stress and increases inflammatory cytokine levels and reduces T-cell numbers in the placenta and impairs thymic development in the infant (Ahmed et al. 2011; [@r39]). Arsenic exposure during pregnancy has also been shown to increase the risk of lower respiratory tract infections during infancy ([@r38]). Recurrent lower respiratory tract infections in early childhood and defective pulmonary immune defenses are important risk factors for the development of non-CF bronchiectasis ([@r20]). In addition, *in utero* exposure to arsenic reduces birth weight, which is associated with worse respiratory health outcomes in later life ([@r16]). Low birth weight infants are more susceptible to lower respiratory tract infections in infancy ([@r31]), have impaired lung function during childhood ([@r6]), and are at an increased risk of death from chronic lung diseases in adulthood ([@r3]). Taken together, these factors suggest that arsenic-induced impairments in growth and development of the lung, along with alterations in immune function, may contribute to the development of bronchiectasis in individuals exposed to arsenic *in utero*.

In the present study, we investigated the effects of *in utero* exposure to arsenic on postnatal lung mechanics, lung structure, and gene expression using mouse models. We hypothesized that *in utero* exposure to arsenic via drinking water impairs lung development and immune pathways in the lung.

Methods
=======

*Animals and exposure to arsenic.* Animals were purchased from the Animal Resources Centre (Murdoch, Western Australia, Australia). Three strains of mice were used; BALB/c, C3H/HeARC \[TLR4 (toll-like receptor 4) intact\], and C57BL/6. Animals were treated humanely and with regard for alleviation of suffering. All studies were conducted according to the guidelines of the National Health and Medical Research Council Australia and approved by the institutional animal ethics committee. Pregnant mice were given drinking water containing 0 (control) or 100 µg/L of arsenic from gestation day (GD) 8 until birth of their offspring (at approximately GD20) in the form of sodium arsenite (NaAsO~2~). The arsenic concentration of drinking water was confirmed by inductively coupled plasma--mass spectrometry (ICP-MS) (Geotechnical Services, Perth, Western Australia, Australia). After their offspring were born, mothers were all given control drinking water. All mice received the same fixed formulation diet (Specialty Feeds, Glen Forrest, Western Australia, Australia). The arsenic content in the mouse chow was determined through ion chromatography ICP-MS to be 0.42 ± 0.02 µg/g total arsenic and 0.03 ± 0.001 µg/g inorganic arsenic (Centre for Environmental Risk Assessment and Remediation, University of South Australia, Mawson Lakes, South Australia, Australia). Outcomes were measured in the offspring at 2 weeks of age (BALB/c, *n* = 29 controls and 24 arsenic exposed; C3H/HeARC, *n* = 14 controls and 17 arsenic exposed; C57BL/6, *n* = 24 controls and 32 arsenic exposed).

*Thoracic gas volume (TGV) and lung mechanics.* To measure lung mechanics *in vivo*, mice were anesthetized, tracheotomized, and mechanically ventilated. Plethysmography was used to measure TGV as described previously ([@r17]). Lung mechanics were measured using the forced-oscillation technique as described previously ([@r46]). \[For further details, see Supplemental Material, p. 2 (<http://dx.doi.org/10.1289/ehp.1205590>).\]

*Stereological analysis of lung structure.* Lung structure was assessed using stereology techniques according to ATS/ERS (American Thoracic Society/European Respiratory Society) guidelines ([@r14]). \[For further details, see Supplemental Material, p. 3 (<http://dx.doi.org/10.1289/ehp.1205590>).\]

*Gene expression profiling studies.* Peripheral lung tissue was excised from mice and stabilized in RNALater (Qiagen, Hilden, Germany) (*n* = 6 litters per treatment group, per strain). The lung tissue was disrupted in TRIzol (Invitrogen, Life Technologies, Carlsbad, CA, USA) employing a rotor stator homogenizer and extracted with TRIzol followed by RNA purification using RNeasy (Qiagen). The quality of the RNA samples was assessed on the bioanalyzer (model 2100; Agilent Technologies, Santa Clara, CA, USA) \[RNA integrity number (RIN) 8.30 ± 0.58\]. Total RNA samples were labelled and hybridized to Mouse Gene ST1.0 microarrays (Affymetrix, Santa Clara, CA, USA) by the Molecular Genetic Research Services, at the Australian Neuromuscular Research Institute, QEII Medical Centre, Nedlands, Western Australia, Australia.

The raw microarray data were pre-processed employing the PLIER+16 algorithm (gcbg background subtraction, quantile normalization, iterPLIER summarization) in Expression Consol software (Affymetrix) ([@r5]). Two low-quality microarrays were removed from the analysis. To identify differentially expressed genes, the data were analysed with moderated *t*-statistics (LIMMA R package; <http://www.R-project.org>) ([@r48]) and plotted as Volcano plots \[see Supplemental Material, Figure S1 (<http://dx.doi.org/10.1289/ehp.1205590>)\]. Genes with an absolute moderated *t*-statistic of \> 3.5 and fold change \> 2 were considered differentially expressed. The microarray data are available from the Gene Expression Omnibus repository (<http://www.ncbi.nlm.nih.gov/geo/>) under accession number GSE37831. A subset of differentially expressed genes was selected for quantitative real-time polymerase chain reaction quantitative real-time polymerase chain reaction (qRT-PCR) validation studies.

*qRT-PCR.* Total RNA was reverse-transcribed with QuantiTect Reverse Transcription Kit (Qiagen) according to the manufacturer's instructions. Primer assays were purchased from Qiagen and qRT-PCR was performed with QuantiTect SYBR Green (Qiagen) on the ABI Prism 7900HT (Applied Biosystems, Life Technologies, Foster City, CA, USA). Relative standard curves were prepared from serially diluted RT-PCR products. Data were normalized to the *Eef1a1* (eukaryotic translation elongation factor 1 alpha 1) gene and multiplied by a scaling factor to obtain whole numbers.

*Quantification of mucous cells and protein in the airways.* We performed airway histopathology and immunohistochemistry to determine the expression of mucus-producing cells and protein expression in the airways. After euthanasia, a tracheal cannula was instilled with 4% formaldehyde at 10 cmH~2~0. Lungs were embedded in paraffin wax and the left lobe was sectioned for airway histology. Alcian blue--periodic acid--Schiff stain was used to detect mucus-producing cells, and immunohistochemistry, using an avidin--biotin--peroxidase complex method ([@r43]), was used to detect cells positive for CLCA3 (chloride channel calcium activated 3 protein), MUC5B (mucin 5, subtype B, tracheobronchial protein), and REG3γ (regenerating islet-derived 3 gamma protein). \[For further details, see Supplemental Material, pp. 3--4 (<http://dx.doi.org/10.1289/ehp.1205590>).\] The expression of mucus-producing and protein-positive epithelial cells was calculated as the percentage of positively stained epithelial cells divided by the total number of epithelial cells in the airway. Airways were classified by their basement membrane perimeter (large \> 1,500 µm, medium \> 1,000 µm, small \< 1,000 µm).

*Statistical analysis.* All statistical analyses were conducted using STATA (version 9.2; StataCorp, College Station, TX, USA). Group means were compared using *t*-tests, analysis of variance, and analysis of covariance (where adjustment for a continuous variable was required). Data were transformed as necessary to satisfy the assumptions of normality and homoscedasticity. A *p-*value of ≤ 0.05 was considered statistically significant.

Results
=======

*Maternal and birth outcomes.* There was no difference in water consumption between mothers given 100 μg/L arsenic compared with control mothers for any strain of mouse (BALB/c, *p* = 0.46; C3H/HeARC, *p* = 0.34; C57BL/6, *p* = 0.82) \[see Supplemental Material, Table S1 (<http://dx.doi.org/10.1289/ehp.1205590>)\]. There were no differences in litter size (BALB/c, *p* = 0.30; C3H/HeARC, *p* = 0.87; C57BL/6, *p* = 0.54) or gestational age at birth (BALB/c, *p* = 0.84; C3H/HeARC, *p* = 0.21; C57BL/6, *p* = 0.31) between arsenic-exposed and control mice. Arsenic-exposed C57BL/6 offspring were smaller in birth weight and birth length compared with control C57BL/6 offspring \[*p* \< 0.001 and *p* \< 0.001, respectively (see Supplemental Material, Table S1)\]. There were no differences in birth weight or length between arsenic-exposed mice and control BALB/c (*p* = 0.15 and *p* = 0.21) or C3H/HeARC offspring (*p* = 0.18 and *p* = 0.78). For all analyses reported there was no difference in responses between male and female offspring, so data were pooled.

*TGV and lung mechanics.* Arsenic-exposed C57BL/6 mice were significantly smaller in body weight (*p* \< 0.001) than control offspring at 2 weeks of age and had significantly lower TGV than controls (*p* \< 0.001), even after adjusting for snout-vent length (*p* = 0.04) \[see Supplemental Material, Figure S2 (<http://dx.doi.org/10.1289/ehp.1205590>)\]. Arsenic-exposed C57BL/6 mice had significantly higher tissue damping and tissue elastance (*p* \< 0.001 in both cases) compared with C57BL/6 controls ([Figure 1](#f1){ref-type="fig"}). These differences were maintained after adjusting for TGV (*p* = 0.006 and *p* = 0.004, respectively). There was no effect of arsenic on airway resistance (*p* = 0.29) in C57BL/6 mice, which was maintained after adjusting for TGV (*p* = 0.78).

![Airway resistance (R~aw~; *A--C*), tissue damping (G; *D--F*) and tissue elastance (H; *G--I*) plotted against TGV for 2-week-old BALB/c (*A*,*D*,*G*), C3H/HeARC (*B*,*E*,*H*), and C57BL/6 (*C*,*F*,*I*) mice exposed to 100 µg/L arsenic via drinking water or control water from GD8 to birth. \**p*\< 0.05 compared with control.](ehp.1205590.g001){#f1}

In C3H/HeARC mice there was no difference in body weight (*p* = 0.38) at 2 weeks of age for arsenic-exposed mice compared with control mice. TGV was significantly higher in arsenic-exposed mice compared with controls (*p* = 0.02), which was maintained after adjusting for snout-vent length (*p* \< 0.001) \[see Supplemental Material, Figure S2 (<http://dx.doi.org/10.1289/ehp.1205590>)\]. At 2 weeks of age, arsenic-exposed C3H/HeARC mice had significantly higher airway resistance compared with controls (*p* = 0.04), which was still higher after adjusting for TGV (*p* = 0.002). There was no effect of arsenic on tissue damping or tissue elastance (*p* = 0.46 and *p* = 0.34, respectively) even after adjusting for TGV (*p* = 0.15 and *p* = 0.65, respectively) ([Figure 1](#f1){ref-type="fig"}).

In BALB/c mice there was no difference in body weight (*p* = 0.31) for arsenic-exposed mice compared with control mice at 2 weeks of age. TGV was significantly higher in mice exposed to arsenic *in utero* (*p* = 0.05); however, there was no difference after adjusting for snout-vent length (*p* = 0.20) \[see Supplemental Material, Figure S2 (<http://dx.doi.org/10.1289/ehp.1205590>)\]. In BALB/c mice there was no difference in airway resistance at 2 weeks of age between the groups (*p* = 0.82), which was also the case after adjusting for TGV (*p* = 0.28). There was evidence to suggest that both tissue damping and tissue elastance were lower in arsenic-exposed mice compared with controls (*p* = 0.07 and *p* = 0.02, respectively); however, these differences were negated after adjusting for TGV (*p* = 0.65 and *p* = 0.22, respectively) ([Figure 1](#f1){ref-type="fig"}).

*Stereological analysis of lung structure.* In C57BL/6 mice, lung volume (calculated by stereology) was significantly smaller in arsenic-exposed offspring compared with controls (*p* = 0.03). The number of alveoli in the lung (*p* = 0.01) and the surface area of the lung (*p* = 0.04) were also smaller in arsenic-exposed C57BL/6 mice compared with control mice of the same strain; however, there was no difference in the volume of the alveoli (*p* = 0.41) ([Figure 2](#f2){ref-type="fig"}). We found no differences in any of the structural parameters measured between arsenic-exposed mice and control BALB/c mice or C3H/HeARC.

![Lung volume (V~L~; *A*), number of alveoli in the lung \[N(a,L); *B*\], alveolar surface area \[S~v~(a); *C*\], and alveolar volume (V~a~; *D*) for 2-week-old BALB/c, C3H/HeARC, and C57BL/6 mice exposed to 100 µg/L arsenic via drinking water or control water from GD8 to birth. \**p*\< 0.05 compared with control.](ehp.1205590.g002){#f2}

*Gene expression profiling studies.* Using microarray analysis, we identified 10 annotated genes in the lung that were differentially expressed as a result of *in utero* exposure to arsenic ([Table 1](#t1){ref-type="table"}). C57BL/6 mice had 7 genes that were differentially expressed, whereas C3H/HeARC mice had 2 and BALB/c mice had only 1 differentially expressed gene(s). Only 1 gene was down-regulated in response to arsenic, *Olfr1274* (olfactory receptor 1274), in the C57BL/6 strain. All of the other genes identified as differentially expressed were up-regulated in response to arsenic exposure.

###### 

Genes altered by arsenic exposure.

  Mouse strain/ gene symbol   Gene name                                                                Function                                                            Reference                  Fold change
  --------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------- -------------------------- -------------
  C57BL/6                                                                                                                                                                                             
  Clca3                       Chloride channel calcium activated 3                                     Regulation of mucus production and secretion                        Zhou et al. 2002           15.05
  Lplunc1                     Long palate, lung, and nasal epithelium carcinoma-associated protein 1   Innate immunity in mouth, nose, and lungs                           Bingle and Craven 2002     13.72
  Reg3γ                       Regenerating islet-derived 3 gamma                                       Innate immunity--antibacterial properties in the mucus secretions   McAleer et al. 2011        8.77
  Scgb3a1                     Secretoglobin, family 3A, member 1                                       Secretary cell subtype in the lung                                  Roy et al. 2011            5.80
  Tff2                        Trefoil factor 2 (spasmolytic protein 1)                                 Innate immunity--allergen induced gene, expressed in mucous cells   Nikolaidis et al. 2003     3.26
  Muc5b                       Mucin 5, subtype B, tracheobronchial                                     Major mucin in respiratory mucus                                    Kirkham et al. 2002        3.16
  Olfr1274                    Olfactory receptor 1274                                                  Olfaction                                                           Zhang and Firestein 2002   --2.07
  C3H/HeARC                                                                                                                                                                                           
  Dynlrb2                     Dynein light chain roadblock--type 2                                     Regulation of TGF-B pathway                                         Jin et al. 2009            2.36
  Sox2                        SRY-box containing gene 2                                                Lung branching morphogenesis and epithelial cell differentiation    Gontan et al. 2008         2.27
  BALB/c                                                                                                                                                                                              
  Ssxb10                      Synovial sarcoma, X member B, breakpoint 10                              Cancer                                                              Chen et al. 2003           2.41

Three of the 10 genes that were up-regulated \[*Clca3*, *Muc5b*, and *Scgb3a1*) (secretoglobin, family 3A, member 1\] are involved in the regulation and/or secretion of mucus in the airways ([@r42]). These genes were all up-regulated in C57BL/6 mice. Four of the 10 genes {*Lplunc1* \[long palate, lung, and nasal epithelium carcinoma-associated protein 1\], *Tff2* \[trefoil factor 2 (spasmolytic protein 1)\], *Reg3*γ, and *Dynlrb2* \[dynein light chain roadblock--type 2\]} that were up-regulated are involved in innate immune function ([@r4]; [@r18]; [@r30]; [@r35]). *Lplunc1*, *Tff2*, and *Reg3*γ were up-regulated in C57BL/6 mice, and *Dynlrb2* was up-regulated in C3H/HeARC mice. We also identified a gene involved in lung branching morphogenesis and epithelial cell differentiation, *Sox2* ([@r12]), which was up-regulated in C3H/HeARC mice. In BALB/c mice, an oncogene \[*Ssxb10* (synovial sarcoma, X member B, breakpoint 10)\] was the only gene up-regulated ([@r9]).

*Validation of array expression using qRT-PCR.* Using qRT-PCR, we validated the expression of four genes in C57BL/6 mice (*Clca3*, *Muc5b*, *Tff2*, and *Reg3g*) and one gene in C3H/HeARC mice \[*Sox2* (SRY-box containing gene 2)\]. In all cases, the expression patterns, normalized to the *Eef1a1* gene, correlated to those obtained in the microarray analysis ([Figure 3](#f3){ref-type="fig"}).

![Validation of microarray gene expression in a subset of genes (*Muc5b, Clca3, Tff2, Reg3*γ, and *Sox2*) using qRT-PCR. All values were normalized to the *Eef1a1* gene. \**p*\< 0.05 compared with control.](ehp.1205590.g003){#f3}

*Quantification of mucus and protein in the airways.* We used Alcian blue--periodic acid--Schiff staining and immunohistochemistry to quantify mucus-producing cells and CLCA3, MUC5B, and REG3γ protein in the airways of BALB/c, C3H/HeARC, and C57BL/6 mice ([Figure 4](#f4){ref-type="fig"}). We found that arsenic exposure *in utero* caused mucous cell metaplasia in the large (*p* \< 0.001) and medium (*p* = 0.02) airways of C57BL/6 mice and increased the expression of CLCA3 (*p* \< 0.01) and REG3γ (*p* = 0.02) proteins in the large airways of C57BL/6 mice ([Figure 5](#f5){ref-type="fig"}). The levels of MUC5B protein were low and not differentially expressed between the airways of arsenic-exposed mice and control C57BL/6 mice. There were no differences in the number of mucus-producing cells or CLCA3, MUC5B, or REG3γ proteins between the airways of arsenic and control mice of either the BALB/c or C3H/HeARC strains (data not shown).

![Airway histology showing that arsenic induces mucous cell metaplasia and increases CLCA3 protein expression in the airways of C57BL/6 mice. Lung sections stained with Alcian blue--periodic acid--Schiff (*A*,*B*) and an antibody to CLCA3 (*C*,*D*) show increased mucous cell (dark purple stain) and CLCA3 protein (brown stain) expression in the airways of C57BL/6 mice exposed 100 µg/L arsenic (*B*,*D*) via drinking water or control water (*A*,*C*) from GD8 to birth. Bars = 200 µm.](ehp.1205590.g004){#f4}

![Quantitation of mucus-producing cells (*A*) and CLCA3-(*B*), MUC5B- (*C*), and REG3γ- (*D*)positive epithelial cells in the airways of C57BL/6 mice. Values are expressed as the percentage of mucus-producing epithelial cells and protein-positive epithelial cells ÷ total number of epithelial cells in large, medium, and small airways of C57BL/6 mice exposed to 100 µg/L arsenic via drinking water or control water from GD8 to birth. \**p*\< 0.05 compared with control.](ehp.1205590.g005){#f5}

Discussion
==========

Exposure to arsenic *in utero* has been shown to increase morbidity from lower respiratory tract infections in infancy and increase mortality from bronchiectasis in adulthood ([@r38]; [@r47]). In the present study, our results show that the response to arsenic in mice is genetically determined and that the C57BL/6 strain is the most susceptible of the three strains studied. *In utero* exposure to arsenic impaired somatic growth, lung volume, and parenchymal lung mechanics in C57BL/6 mice. In addition, exposure to arsenic during gestation is capable of altering the expression of genes that function in mucociliary clearance, innate immunity, and lung growth in the offspring. Arsenic also induced mucous cell metaplasia and increased expression of CLCA3 protein in the airways of C57BL/6 mice. Increased mucus secretion and altered lung growth may impair the ability of the airways to clear pathogens and thus provide a potential mechanism by which exposure to arsenic increases the risk of developing chronic localized infections leading to bronchiectasis.

Exposure to arsenic *in utero* impaired intrauterine growth and lung development. Arsenic-exposed C57BL/6 mice were small for gestational age; had lower lung volume, lung surface area, and alveolar number; and had impaired lung mechanics compared with control mice of the same strain. This finding supports results from a recent study that also found that C57BL/6 mice exposed to arsenic *in utero* had deficits in growth in early life ([@r24]). Impairments to body size and lung size during infancy may result in airways and alveoli that are prone to closure and collapse, thus increasing the susceptibility to obstruction and increased pathogen load. Low birth weight is associated with impaired lung function and increased mortality from obstructive lung disease ([@r3]; [@r15]). A potential mechanism for the observed intrauterine growth restriction may be oxidative stress caused by arsenic-induced production of reactive oxygen species inducing placental insufficiency ([@r49]). This proposed mechanism is supported by the knowledge that the mouse strain most sensitive to arsenic, C57BL/6, is highly susceptible to the oxidative stress effects of cigarette smoke and bleomycin compared with other strains ([@r7]; [@r52]). There is evidence from cigarette smoke exposure models that intrauterine growth restriction alone can cause alterations in early life lung function ([@r26]). It is therefore possible that the effects of arsenic exposure on body weight, lung function, and lung size in the present study, in the C57BL/6 mice at least, were due to arsenic altering the nutritional status of the offspring. However, we also identified responses, such as alterations in lung gene expression and airway morphology that seem to be unique to arsenic exposure and have yet to be linked with altered nutritional status. It is clear that exposure to arsenic during pregnancy is having a significant effect on intrauterine growth, which may predispose infants to chronic lung diseases through impairments in lung growth and development.

We found that arsenic exposure during pregnancy was capable of altering the expression of genes in the lung at 2 weeks of age. The differentially expressed genes identified are involved in mucus production, innate immunity, and lung morphogenesis pathways. The gene that was most highly up-regulated was the calcium-activated chloride channel, *Clca3* gene. This gene has been detected in goblet cells within the tracheal and bronchial epithelium of mice when metaplasia of mucous cells is present ([@r28]) and is thought to play a role in the mucus hypersecretion seen in chronic obstructive pulmonary disease (COPD) and CF in humans ([@r40]; [@r44]). Blocking the production and/or activity of *Clca3* can inhibit the production of mucus, whereas up-regulation can enhance mucus production ([@r55]). *Clca3* has been implicated in the regulation of mucus secretion by controlling the packaging and/or release of secreted mucins such as MUC5AC and MUC5B, which are the major gel-forming mucins in respiratory secretions ([@r32]; [@r55]). MUC5B levels are increased in sputum from the airways of patients with COPD and CF compared with sputum from healthy airways ([@r21]) and are associated with the overproduction of mucus in diseased airways ([@r8]). In our study, *Muc5b* gene expression was also up-regulated and mucous cell metaplasia was present in the airways of C57BL/6 mice. Mucous cell metaplasia is a pathological feature of various respiratory diseases including both CF and non-CF bronchiectasis, COPD, and asthma ([@r19]). Mucus hypersecretion can hinder the ability of the cilia to clear mucus from the airways, thus increasing the susceptibility to viral and bacterial colonization and infection ([@r44]). Increased mucus in the airways may also lead to obstruction and contribute to abnormalities in lung mechanics ([@r41]). Increased mucus production resulting in increased susceptibility to respiratory infections combined with airway obstruction can lead to chronic localized inflammation: a hallmark of the bronchiectatic lung ([@r2]).

As well as increasing the risk of infection, arsenic exposure *in utero* may compromise the immune response to respiratory infections. In the present study, we identified four genes that play a role in modulating the immune system that were up-regulated by exposure to arsenic. TFF2 protein has a role in mucosal epithelial restitution and wound healing in the gastrointestinal tract ([@r37]). In the lung, TFF2 protein expression is increased in mucous cells of allergen-challenged mice and is up-regulated in airway epithelial cells in subjects with asthma ([@r25]; [@r34]). *Tff2* has also been identified as a candidate gene associated with strain-dependent differences in lung function in mice ([@r10]). REG3γ is a protein with antimicrobial activity identified as playing a role in innate mucosal immunity in the gastrointestinal tract ([@r54]) and more recently in the lung ([@r30]). *Dynlrb2* is differentially expressed in patients with primary ciliary dyskinesia, a condition that can lead to the development of bronchiectasis due to impairment of mucociliary clearance ([@r11]). *Dynlrb2* has also been shown to regulate the TGF-β (transforming growth factor, beta) signalling pathway ([@r18]). Increased production and activation of TGF-β has been linked to immune defects associated with the susceptibility to opportunistic infection ([@r27]). LPLUNC1 is a protein suggested to play a role in innate immunity in the lung, mouth, and nose, through either direct antibacterial actions or by indirect neutralizing activity ([@r4]). Mucous cell metaplasia and altered immune pathways in the lung may partially explain the increased susceptibility to and exacerbated response to influenza infection seen in a mouse model of arsenic exposure ([@r22]). Importantly, compromised innate immune pathways in the lung during infancy may increase the risk of respiratory infections in early life, when susceptibility to infection is high, and increase the risk of developing chronic lung disease in adulthood.

To put these observations into context, we recognize that there were some limitations to the present study. In the mouse chow given to all the mice in our study, there was a small amount (0.03 µg/g) of inorganic arsenic, which has the potential to alter gene expression in the liver and lung ([@r23]). However, the concentrations of inorganic arsenic in our study were low, the same diet was given to all of the mice, and we still detected differences in a variety of outcomes, including gene expression, as a result of the exposure to 100 µg/L arsenic in drinking water. Another limitation of the study is that only a single concentration of arsenic (100 µg/L) was used in our study. This represents a relatively high concentration of arsenic \[10 times higher than the current World Health Organization (WHO 2011a) maximum contaminant level\], and the effects observed in the present study may not reflect changes that would occur at higher or lower doses. In the present study, we identified only a small number of genes that were differentially expressed as a result of arsenic exposure. Even by relaxing our criteria for differential expression, we were not able to identify any functionally coherent pathways using more complex methods of analysis. Because we assessed the lung tissue sometime after the arsenic exposure had ceased, it is possible that we missed some pathways and there is value in examining expression networks in lung tissue during exposure in the future ([@r36]). Our study, however, has identified and validated a number of genes that we believe provide important clues to the underlying mechanisms and, given their function, are likely to be important in the lung disease phenotype induced by arsenic exposure in humans (e.g., infection/bronchiectasis). In addition, we examined the effects of arsenic exposure on the lung in offspring at only 2 weeks of age in the present study. The long-term effects of arsenic exposure on lung development may differ between strains whereby changes in parenchymal growth may manifest at different ages ([@r33]). An analysis of later time points may provide further information about the genetic basis of susceptibility to arsenic-induced lung disease.

Conclusions
===========

In the present study, we have shown that *in utero* exposure to arsenic via drinking water impairs lung development, resulting in reduced lung size and impaired lung structure and function. The response to arsenic is genetically determined and the C57BL/6 strain is the most susceptible. Arsenic exposure *in utero* altered the expression of genes that regulate innate immunity, mucus production, and morphogenesis of the lung. Arsenic-induced alterations in the development of lung structure and innate immunity may reduce the ability to clear respiratory pathogens during a period of high susceptibility in infancy ([@r45]). Because respiratory infections are one of the leading causes of mortality in children under 5 years of age in developing countries (WHO 2011b), arsenic-induced increases in susceptibility to infection can have devastating effects on infant morbidity and mortality in affected areas. In addition, recurrent respiratory infections throughout life can contribute to the development of chronic lung diseases, such as bronchiectasis, in adulthood. The evidence from our mouse model is that *in utero* exposure to arsenic impairs lung development, resulting in altered structure, function, and gene expression in infancy. Further investigation into how arsenic affects lung development in humans will be essential to understand and prevent escalating morbidity and mortality from respiratory disease in arsenic-exposed populations.
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